Judges for 2014 Hippocrates Prize for Poetry and Medicine

Members of the judging panel for the 2014 Hippocrates Prize are poet Philip Gross, a winner of the TS Eliot Prize, distinguished barrister Robert Francis QC, and Mumsnet Editor Sarah Crown, and for the Young Poets category Kit Wright.

The Hippocrates Prize is for an unpublished poem in English of up to 50 lines text, excluding title and line spacing.

With a 1st prize of £5,000 both for the winning poem in the Open International category and for the NHS category, the Hippocrates Prize is one of the highest value poetry awards in the world for a single poem. There is also an international category for Young Poets aged from 14 to under 19 years. This £500 award was launched in 2012, and is for an unpublished poem of up to 50 lines in English on a medical theme.

In its first 4 years, the Hippocrates Prize has attracted around 5000 entries from 55 countries, from the Americas to Fiji and Finland to Australasia.

Entries are now open for the 2014 Hippocrates Prize for poetry and medicine, deadline 31st January 2014. There is no limit to the numbers of entries by any poet.

Awards will be presented at the 5th International Symposium for Poetry and Medicine, to be held on Saturday 10th May, 2014 in London.

Philip Gross’s The Water Table won the T.S.Eliot Prize 2009, I Spy Pinhole Eye Wales Book of The Year 2010, and Off Road To Everywhere the CLPE Award for Children’s Poetry 2011. Deep Field (2011) deals with voice and language, explored through his father’s aphasia, and a new collection, Later, is due from Bloodaxe in Autumn 2013. He has published ten novels for young people, including The Lastling, has collaborated with artists, musicians and dancers, and since 2004 has been Professor of Creative Writing at Glamorgan University, where he leads the Masters in Writing programme. [Photo by Stephen Morris]

Robert Francis QC is a distinguished barrister who specialises in the NHS and medical negligence. He has been a Queen's Counsel for 21 of his 40 years at the bar. He has been involved in many inquiries into the NHS, both as barrister and as chair, most recently chairing the inquiry into the Mid Staffordshire Hospital. According to Peter Walsh, chief executive of the patient safety charity Action against Medical Accidents, Robert Francis has a "passion for justice in healthcare and improving healthcare more generally".

Sarah Crown is editor of Mumsnet. She was editor of Guardian Books from 2007-2013. Previous poetry awards for which she has been a member of the judging panels include the Forward prizes and the Picador poetry prize.

The 2014 Hippocrates Young Poets Prize for Poetry and Medicine will be judged by poet Kit Wright, one of the most acclaimed poets for adults and children. Kit Wright is the author of more than twenty-five books, for both adults and children, and the winner of awards including an Arts Council Writers' Award, the Geoffrey Faber Memorial Prize, the Hawthornden Prize, the Alice Hunt Bartlett Award and (jointly) the Heinemann Award. After a scholarship to Oxford, he worked as a lecturer in Canada, then returned to England and a position in the Poetry Society.

The Hippocrates poetry and medicine initiative received  the Award for Excellence and Innovation in the Arts in the 2011 Times Higher Education awards.

Winners of the 2013 Hippocrates Prize:

Harvard poet and physician Rafael Campo wins Hippocrates Open International Prize for Poetry and Medicine

Psychotherapist Mary V Williams wins Hippocrates NHS Prize for Poetry and Medicine
English poet 

Rosalind Jana awarded international Hippocrates Young Poets Prize for Poetry and Medicine

For email enquiries about the Hippocrates Prize:  hippocrates.poetry@gmail.com

Hippocrates website: http://hippocrates-poetry.org

First test of new French artificial implantable heart

A first patient has been fitted with a new French artificial heart. 

Watch interview on @AJEnglish:  

Heart failure is one of the commonest causes of urgent admission to hospital. Modern drugs – and their effective use in combination - have dramatically improved treatment of heart failure. However in many patients heart failure is a progressive disorder and perhaps 100,000 patients in USA and Europe alone are candidates for a new heart. Conventional organ transplantation is limited by availability of a donor heart, the complexity of immunosuppression and other major risks of the procedure.

The dual ambition of the company behind this new technology is an implantable heart which will both allow return to good quality of life for at least 5 years, and be subject to a lower risk of serious complications then earlier devices.

Implanting an artificial heart while awaiting a heart transplant is not a new idea. The first sustained success was for the Jarvik device, first used over 30 years ago. And current implantable devices have been reported to be successful for almost 4 years.

The new Carmat heart is lined with a combination of synthetic polymers and treated tissues from the heart sac (pericardium) of the cow. This aims to reduce the chance of blood clotting on the internal lining of the heart – an important potential risk from an artificial heart. And partnership with aerospace engineers has lead to new biofeedback sensors in the Carmat device.

If experience over the next year or so of the heart in patients confirms the promise of laboratory studies, patients and health professionals might have access to the new device for clinical use by 2015.

However it will of course take at least until 2020 to confirm whether, in general use, the hoped for 5 year lifespan of the device is confirmed for patients who have severe heart failure.

For the benefit of patients, health services and policy makers, there will need to be serious engagement with the biotech industry to ensure that economies of scale in clinical practice reduce dramatically the current huge cost per device - estimated at 140-180,000 €  ie around $240,000.

Four schools receive 2013 Healthy Heart Awards from Mediterranean Diet researcher Ramon Estruch

The 2013 Healthy Heart Awards have been awarded to Chevening CE Primary School in Kent, Corpus Christi Catholic Primary School in Lambeth, Dulwich Hamlet Junior School in Southwark, and St Nicholas CE Primary School in Chislehurst.

The Awards were presented in London on Thursday 5th December 2013 by Mediterranean diet researcher Professor Ramón Estruch from Barcelona.

The aim of the 'Healthy Heart Awards' is to engage young and older school and college students in the health of their hearts. Entries included a short video, artwork, games, and poems about how to keep the heart healthy.

The Healthy Heart Awards were founded in 2010 by healthy heart charity the Cardiovascular Research Trust (CVRT).

Awards co-founder and CVRT trustee Professor Donald Singer said: “The Awards provide an innovative way for young people to make an active contribution to the future health of their own hearts and those of children of all ages from around the world.”

Fellow Awards co-founder and CVRT trustee John Jackson added: “The Healthy Heart Awards also provide new opportunities within the curriculum for teaching and learning about science and health”.

Awards co-organizer Wendy French said: “We are delighted that participating pupils enjoyed taking part, while learning more about keeping the heart healthy”. She added: “Comments from the pupils included:

'It brought us together as a class.'

'It gave me something exciting to think about. I like inventing.'

'It made us solve puzzles about how things could work and sometimes they didn't!'

'I didn't know learning could be such fun.'“

The Awards ceremony, which included readings by Dr Raphael Shirley of winning entries, took place at an international CVRT symposium on ‘Diet, Active Lifestyle and Cardiovascular Health’ on Thursday 5th December 2013.

Symposium speakers included Professor Dame Carol Black, Cambridge, on working for a healthier tomorrow, Professor Ramon Estruch, Barcelona, on protecting cardiovascular health by following a Mediterranean diet, Dr Ingmar Wester, Finland, on plant bioactives to reduce cardiovascular risk, and Professor Chris Imray, Coventry, on exercise to improve outcomes of surgery.

Notes for editors and schools

For more on the Healthy Heart Awards including pictures from the day, contact the Cardiovascular Research Trust on cvrtrust@gmail.com

Information for entries to 2014 Healthy Heart Awards.

The Cardiovascular Research Trust (CVRT) is a registered charity, which supports research and education aimed at prevention and treatment of premature disease of the heart and circulation: http://cvrt.org.uk/

Awards Symposium topics and speakers

Working for a Healthier Tomorrow: Professor Dame Carol Black, DBE, FRCP, Principal of Newnham College Cambridge, Adviser on Work and Health at the Department of Health, England, Chair of the Nuffield Trust and Chair of the Governance Board, Centre for Workforce Intelligence. Spearheaded by Carol Black as National Director, ‘Health, Work and Wellbeing’ is a joint initiative across government to improve the health and well-being of working age people.

Mediterranean diet and cardiovascular health: Professor Ramón Estruch, Medical Professor at the University of Barcelona. He leads Thematic Networks evaluating the effects of the Mediterranean Diet and its main components on primary prevention of cardiovascular disease in high-risk patients. He is also a member of the Advisory Committee of the EU European Foundation for Alcohol Research.

Healthy Heart Awards co-organizer: Wendy French was head of the Maudsley and Bethlem Hospital School for fifteen years and now works with people with aphasia/dysphasia, helping them to recover their use of language through poetry. With fellow poet Jane Kirwan, in 2013 she published Born in the NHS, a passionate defence of the NHS and a social history – families in sickness and health, the changing roles of health professionals – over the last seventy years.  Her prizes in international competitions include first prize in the NHS category of the Hippocrates Prize in 2010 and second prize in 2011.

Exercise and improving outcome of surgery: Chris Imray, Professor of Vascular Surgery at the University Hospital in Coventry. He is interested in the effects of extreme altitude on the cardiovascular system, in prevention and treatment of carotid artery stroke syndromes, and in strategies for improving outcomes of vascular surgery.

Reader of entries for the Healthy Heart Awards: Dr Raphael Shirley performed at the Edinburgh Festival in 2012 and 2013. For more see Raph’s website: http://www.raphshirley.com

Diet and exercise to reverse overweight: what works? Donald Singer, Professor of Clinical Pharmacology & Therapeutics at the University of Warwick. Professor Singer is interested in prevention and treatment of cardiovascular disease, and in public understanding of the benefits and risks of medicines.

The Lifestyle Heart Trial: 23 years on. Dr Ellen Storm, is a medical doctor training in paediatrics and child health. She has a Masters Degree in public health and has a particular scientific interest in the causal relationships between diet and disease.

Plant stanols, blood lipids and cardiovascular health: Dr Ingmar Wester, R & D Director at Finnish company Raisio. He discovered plant stanol esters in 1995 and has researched their cardiovascular benefits.

Personalising medicines: good or bad for health of the public

"Me Medicine vs. We Medicine: reclaiming biotechnology for the common good".
Donna Dickenson. Columbia University Press, New York. 2013.

The key premise of this seductive book by Donna Dickenson is that 'we medicine' - medicine aimed at maximizing the health of the nation, and 'me medicine' - medicine customised for individual patients, are mutually exclusive. The author, an Emeritus Professor of Medical Ethics and Humanities at the University of London, chooses to focus on new molecular diagnostics, including  pharmacogenetics and pharmacogenomics, as the major relevant examples of personalised medicines. The author bases much of her argument on her perception of the polarity that 'genetics and genomics reveal more profound truths than other sciences'. However there is no clinical consensus that these are disciplines that operate in isolation. Genetics and genomics complement other medical sciences.

Good therapeutic practice concerns applying a wide range of clinical and laboratory tools to select the right drug(s) for the right disease and the right patient, at the right time, at the right dose, by the right route of administration, and for the right duration. Personal biomarkers of treatment response which should be used as a regular part of good medical practice include age, gender, ethnicity, lifestyle, co-morbidity, concomitant prescribed and non-prescribed regular and occasional medicines, and key lab phenotypes, such as renal and liver function, in addition to emerging pharmacogenetic and pharmacogenomic tests. By using these tools to apply a personal approach to patient management, prescribers are more able to select effective treatment options, and less likely to select treatments that may cause serious adverse effects ..

For more, see my review in Pharmacology Matters, a publication of the British Pharmacological Society.

Drugs and Pharma: a matter of trust?

Medicines have significant costs, both financial and in terms of serious adverse effects. Treatment

should therefore only be prescribed and continued when the benefit outweighs the risk. This presupposes that health professionals, patients, and policymakers have trustworthy evidence to support clinical use of medicines.

It is vital that research on medicines is objective in order to show whether proposed treatments are effective for improving clinically meaningful outcomes for patients, how they compare to existing remedies, and the relative and absolute cost implications of adopting the treatment.

In his seductive polemic Bad Pharma, psychiatrist and 'Bad Science' Guardian columnist Ben Goldacre raises major concerns about the quality of evidence on the efficacy and safety of specific drugs and classes of treatment in clinical use. His book has added to recent public concern about medicines, their safety, and the probity of pharmaceutical companies.

This background concern for the public has been inspired both by works of fiction, for example the film Side Effects, set within a corrupted psychotherapeutic sector, and John Le Carre's African novel The Constant Gardener, which raises important questions about the ethics of clinical research on anti-infective agents in developing countries.

And by a series of very large fines imposed on major pharmaceutical companies for a wide range of reported major errors of omission and commission, including concealed data on safety, and encouragement of doctors to prescribe off-licence, i.e. to patient groups for whom there is no or insufficient evidence on effectiveness or safety of medicines.

See more in reviews in the Reinvention Journal

Ben Goldacre Bad Pharma: How drug companies mislead doctors and harm patients.
London: Fourth Estate. Reprinted with edits: February 5, 2013 | ISBN-10: 0865478007 | ISBN-13: 978-0865478008

Not so smart drugs: concerns about modafinil

Modafinil has been in medical use since the late 1980s to improve alertness.

Because of concerns about serious medical risks, medical use has been restricted to treating narcolepsy since 2010 by the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency.

Students and employees, young and old, are being tempted to use 'smart' drugs to try to improve their academic or professional performance. This use of modafinil is not medically licensed - the aim of improving the effectiveness of learning and performance in exams, and other educational assignments.

The drug is reported to be in widespread use by students in Germany, the UK, the US and elsewhere in the hope that it will improve studying, learning and exam performance.
 

How is modafinil thought to act? Its mode of action is unknown. Suggested mechanisms include orexin-mediated enhancement of a range of brain activation neurotransmitters (norepinephrine, dopamine, histamine, serotonin) in brain arousal centres; and increased gap junction communication from brain cell to brain cell.

Does modafinil improve intellectual performance? At best, it is considered no substitute for a healthy sleep pattern. There have been two types of formal study – those in well-slept healthy young or older subject; and studies in sleep deprived subjects. Typically, studies are of a single dose, and medical or psychiatric disorders, and use of other medical drugs, or recreational drugs (including caffeine, alcohol and nicotine) are reasons for exclusion from studies of modafinil.

Studies of possible effects of modafinil on studying and learning are typically based on artificial tests – ie do not test for possible benefits of the drug on what students may be trying to learn, or results of the types of exams students may be sitting. Results are conflicting. In high IQ young subjects, performance of highly complex psychological tests, but not less complex tasks, may be improved. More focused study, with however increased response time has also been reported.

Anecdotally, students have reported that the drug appears to lead to more efficient completion of a deadline but not improvement in content. However these perceptions are vulnerable to placebo responses.

Only a handful of good quality studies have been performed on the possible effects of modafinil on cognition. These have involved psychological model tests, not studies of how well students learn course or professional materials. There remains the need for study of effects and risks of repeated use of modafinil in real world settings using tests relevant to the study activities of students.

Side effects? There are many – from loose bowels, to loss of effectiveness of the oral contraceptive pill, leading to unwanted pregnancy, and rare but life-threatening and fatal skin reactions Stevens-Johnson Syndrome).

Further important side effects include sleep disturbance and neuropsychiatric disorders indirect reasons why performance might be impaired by the drug.

There are also reports by users that in response to modafinil too much focus on details may make it difficult both to complete an assessment and to consider a broad enough range of issues to give a complete answer.

Risks of modafinil may be greater if there are unrecognized problems, in particular if the user has a medical history of cardiovascular or psychiatric problems. Use without clinical advice may mean that important underlying conditions are not identified, for example high blood pressure, disorders of heart rhythm, and psychiatric risk; and potential important interactions with other drugs (including other stimulants) may not be considered.

Modafinil has clinically significant effects on the activity of liver enzymes and drug transporters which are important in the handling and clearance of a wide range of common drugs, including digoxin and warfarin.

Older people are more likely to have medical disorders and to be on treatment which might lead to increased risk from modafinil. A particular concern is that these markers of increased risk may not be considered when off-licence supplies are being sought in the hope that there may be benefit for professional work, or as an aid to studying – for example for revalidation.

  
Is use of modafinil any different from using caffeine? Because of the lack of convincing evidence of real world benefit from modafinil and concerns about serious risks, the drug is not approved for use in the absence of a specified medical condition. There are to date no convincing studies showing a benefit from modafinil in long-term use or for specific types of learning or testing relevant to students.

As for other drugs, the balance between risk and benefit must be considered by prescriber and user. In the event of any benefit for studying from the drug, others not using it are put at a disadvantage. 

In contrast caffeine is widely available for those who chose to use it. Too much caffeine, or sensitivity to caffeine can cause troublesome symptoms, including anxiety, tremor, sleep disturbance and palpitations.

Risks from accessing modafinil  from internet pharmacies? For the above reasons, licensed pharmacies would not supply modafinil in the absence of specified medical conditions. Unlicensed internet pharmacies should be avoided. The quality of medicines is not reliable, with serious risk of being supplied poorly active or counterfeit or contaminated medicines. And medical contra-indications need to be identified and discussed to minimize the risk of preventable serious adverse effects.

Fairness and coercion There are also a number of ethical concerns including: the need to protect students and others from using so-called ‘smart drugs’ in response to pressure to compete, both in exams and in professional life; being fair to other students who do not have access to the drug, or do not wish to use what may be a medically harmful pharmacological aid to improving performance in examinations or to meeting challenges at work.

See also
- June 2009: Opposing opinions in the British Medical Journal from John Harris and Anjan Chatterjee

-  Methylphenidate (Ritalin) – does use by ‘healthy’ students matter?

Science meets life and death in Venice

In Venice during this weekend, a major international organisation was launched: the

Hippocrates Society for Poetry and Medicine. This launch marks the 5^th year of the hugely successful Hippocrates initiative, which has attracted interest from 55 countries in its major awards and symposia.

Within the increasingly administered and technical world of medicine, patients often find it difficult to engage with prevention and treatment of common and serious medical problems.

Poetry provides a huge opportunity for patients to gain insight into their illness, as well as to help health professionals to understand better the concerns of their patients. 

Applications are welcome from anywhere in the world to join the Hippocrates Society for Poetry and Medicine from health professionals and patients, from poets and academics, and others who are interested in our aims.

See the full Hippocrates Society Press Release.

How to enter for the 2014 Hippocrates Open International, International Young Poets, and NHS Awards.

Chemical genomics, bioactive molecules and alternative reading frame proteins: clues to sudden cardiac death

The cardiac drug flecainide was developed to prevent and treat serious ventricular tachycardia arrhythmias - very rapid heart rates which, if unchecked, can be lethal. However, in clinical trials, flecainide and its sister molecular encainide were reported to more than double the risk of sudden cardiac death.

Joint work by researchers in Chemistry and Medicine at the University of Warwick, and at the Biotech Company SEEK, is now allowing insight into how cardiac death risk might be increased by these drugs. The methods involve persuading viruses to provide a read-out on their surface of proteins related to human diseases.

In experiments just published in the Royal Society of Chemistry journal Chem Comm, we show that proteins from the heart may be read abnormally - through slippage in the letters of the genetic code for heart muscle components - these are called alternative reading frame proteins, a bit like a very simple old cipher.

Furthermore, flecainide is able to interact with a particular abnormally read protein. Previous research has linked this type of abnormality to serious side-effects of a drug used to treat the developing world parasitic infection Schistosomiasis.

There are two obvious implications of our new work. Testing for these abnormal proteins could be a new way to identify people and their family members who should be protected from risk of serious cardiac problems - for example by avoiding triggers of heart arrhythmias and by considering implantable defibrillators.

And by understanding how flecainide interacts with the abnormal protein, there may be clues to new treatments to interfere with the part of protein linked to cardiac problems.

Adverse effects of drugs can be very serious. When chosing a medicine, prescribers need to be aware of the balance of risks and benefits, and to chose the right drug for the right patient and the right disease, at the right time and for the right duration - long enough but not too long.

However our work shows an unexpected consequence of adverse effects of a drug: providing clues to new causes for disease and new ideas for treatments.

Cutting nerves in the neck to treat high blood pressure?

According to an experimental study published in Nature Communications, severing key nerves in the

neck may provide a new option for lowering high blood pressure.

Considering new approaches to treating high blood pressure (hypertension) is crucial. High blood pressure is a very common and important cause of disease and death resulting from problems with the heart, and with the blood vessels in the body and brain.

Treatment to lower high blood pressure is supposed to continue for decades. However, even by 12 months after the starting treatment, around 50% of patients are not taking their tablets regularly, if at all.


See more ...

Leprosy, from old Spittals to modern times

The Berwick-on-Tweed leper hospital (Spittal) is said to have been established in 1234, at what is now called Spittal Beach. This coincides with the middle of the peak of reported leprosy in Great Britain as being 12th and 13th centuries. London eventually had 10 hospitals for lepers on main routes out of the city. The last recorded case of leprosy in London was said to be in 1559. St Bartholomew was associated with lepers in medieval times, with associations between leper hospitals and churches named after the saint both in Berwick and near London. The name leprosy is derived from the Greek word for scales (lepra), the disease discussed by Hippocrates, with evidence that it was known in Ancient Egypt at least 6000 years ago.

What was like to be leper in medieval times? Lepers lost their rights under common law, including property rights. They were excluded from places where people gathered. They had to carry a bell to warn others of their presence. They were isolated, typically sent away to remote hospitals with chapels, as lepers were expected to follow Christian rule. Hospitals were usually run by religious orders. The reportedly well-funded Berwick hospital was later by Royal Charter of James 1 of Scotland in the charge of the King's Chaplain, Thomas Lauder.

RC St Clemens, ex Benedictine Cloisters, Bad Iburg

Squints or hagioscopes allowed people with leprosy and other infectious diseases to view the sacraments from outside a church of without coming into contact with the healthy members of the congregation.

Historically people with leprosy were recognized because of resulting deformities and were shunned because of fear of contagion. Untreated, leprosy could progress, causing serious disease and deformity to nerves, skin, nerves, limbs and face, including flattening of the nose due to destruction of underlying cartilage, and associated changes in the quality of speech.

A stone tower was erected at the Spittal in Berwick in 1369 as look-out point and protection from raids over the nearby border by the Scots. The buildings were demolished and nothing above ground remains.

Red staining of organism that causes leprosy

We now know that the disease is caused by a bacterium similar to the one that causes tuberculosis: the leprosy version - mycobacterium leprae - discovered by Paul Hansen, leading to the eponymous name Hansen's disease for leprosy. There is a wide spectrum of clinical features of leprosy. The main route of spread to susceptible people considered to be by nasal droplets (from coughing and sneezing). Risk of acquiring the infection appears linked to causes of impaired cell-mediated immunity, prolonged exposure to infected patients, and to malnutrition. Although infants may develop the disease, the incubation period may be as long as 30 years.

Does leprosy still exist? The World Health Organization  records official data on leprosy from up to 120 national programmes in Member States, results published in  the WHO's Weekly Epidemiological Record. From this data, the WHO estimates that one person in 10,000 is affected by the disease (prevalence). New case detection is estimated to have decreased from around 760,000 in 2002 to around 200,000 in 2011 . With early combination drug treatment before deformity (usually for 6-12 months), outcome of the disease is much improved. However, patients with treated leprosy may still be ostracised, especially in rural communities, even if patients are known to have been treated,  because of ignorance about the low risk of disease transmission and about the success of treatment: people are considered no longer infectious after around one week of treatment and it is estimated that over 10 million people estimate cured of leprosy in past 2 decades.

See
Professor Carole Rawcliffe, Medieval History, University of East Anglia
Leprosy in Medieval England, 2006.